Tags : Chronic Spontaneous Urticaria (CSU)

Regulatory

Novartis’ Xolair (omalizumab) Receives EU’s Approval for Severe Allergic Asthma

Shots: The approval is based on trial results assessing Xolair IV (q2w or q4w) in 1M patients with SAA and CSU for 13 years The study demonstrated in reduction of severe exacerbations, corticosteroid use in SAA patients and reduction in symptoms of CSU with safe and well-tolerated results Xolair (omalizumab) is a prefilled syringe (PFS) self-administered syringe, used for targeting  […]Read More